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Developmental prosopagnosia (DP) is characterised by a severe lifelong impairment in face
recognition. In recent years it has become clear that DP affects a substantial number of
people, yet little work has attempted to improve face processing in these individuals.
Intriguingly, recent evidence suggests that intranasal inhalation of the hormone oxytocin
can improve face processing in unimpaired participants, and we investigated whether
similar findings might be noted in DP. Ten adults with DP and 10 matched controls were
tested using a randomized placebo-controlled double-blind within-subject experimental
design (AB-BA). Each participant took part in two testing sessions separated by a 14e25 day
interval. In each session, participants inhaled 24 IU of oxytocin or placebo spray, followed
by a 45 min resting period to allow central oxytocin levels to plateau. Participants then
completed two face processing tests: one assessing memory for a set of newly encoded
faces, and one measuring the ability to match simultaneously presented faces according to
identity. Participants completed the Multidimensional Mood Questionnaire (MMQ) at three
points in each testing session to assess the possible mood-altering effects of oxytocin and
to control for attention and wakefulness. Statistical comparisons revealed an improvement
for DP but not control participants on both tests in the oxytocin condition, and analysis of
scores on the MMQ indicated that the effect cannot be attributed to changes in mood,
attention or wakefulness. This investigation provides the first evidence that oxytocin can
improve face processing in DP, and the potential neural underpinnings of the findings are
discussed alongside their implications for the treatment of face processing disorders.
ª 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. Centre, Poole House, Bournemouth University, Fern Barrow, Poole BH12 5BB, UK.
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c o r t e x 5 0 ( 2 0 1 4 ) 5 5e6 3561. Introduction emotional expressions, and existing studies have reportedFace recognition is an important cognitive skill that most
people take for granted, yet it depends on a complex set of
cognitive and neural processes (Bruce & Young, 1986; Haxby,
Hoffman, & Gobbini, 2000). In some individuals this process
can be selectively disrupted, resulting in a condition termed
“prosopagnosia” or “face-blindness”. While prosopagnosia
can be acquired following brain injury (e.g., Damasio,
Damasio, & Van Hoesen, 1982), many more individuals sim-
ply fail to develop normal face recognition abilities (e.g., Bate,
Haslam, Jansari, & Hodgson, 2009; Bate, Haslam, Tree, &
Hodgson, 2008; Behrmann & Avidan, 2005; Bentin, Deouell, &
Soroker, 1999; Duchaine, Germine, & Nakayama, 2007;
Duchaine & Nakayama, 2006; Jones & Tranel, 2001; Schmalzl,
Palermo, Green, Brunsdon, & Coltheart, 2008). The latter
form of the disorder has been termed ‘developmental proso-
pagnosia’ (DP; but for a discussion of terminology see Susilo &
Duchaine, 2013), and has been attributed to a failure to
develop the visual recognition mechanisms necessary for
successful face recognition, despite intact low-level visual and
intellectual functions. Interestingly, there also appears to be a
genetic component to the disorder in at least some individuals
(Duchaine et al., 2007; Grueter et al., 2007). In the last decade it
has become increasingly clear that DP represents a significant
clinical disorder, with recent reports suggesting that two
percent of the population have the condition (Bowles et al.,
2009; Kennerknecht et al., 2006).
Although many studies have investigated the cognitive,
neural and genetic basis of DP, little attention has beendirected
towards improving face recognition in these individuals. While
some researchers have attempted to remedy face processing
deficits using extensive visual training programmes (e.g.,
DeGutis, Bentin, Robertson, & D’Esposito, 2007; Schmalzl et al.,
2008), recent evidence suggests that an alternative methodol-
ogywarrants investigation.Specifically, insomecircumstances,
intranasal inhalation of the hormone oxytocin has been found
to improve face processing in both healthy participants (e.g.,
Rimmele, Hediger, Heinrichs, & Klaver, 2009; Savaskan,
Ehrhardt, Schulz, Walter, & Schachinger, 2008) and individuals
with autism (Andari et al., 2010).
Oxytocin is a nonapeptide centrally involved in the regu-
lation of basic social and reproductive behaviours, such as
cohabitation, gestation, and breastfeeding. It has been found
to be crucial for social recognition, grooming, approach
behaviour, sexual activity and stress regulation in non-human
mammals (e.g., Carter, 1998; Ferguson, Aldag, Insel, & Young,
2001; Lim & Young, 2006). Recent evidence demonstrates that
oxytocin also facilitates social cognition and pro-social
behaviour in humans (Baumgartner, Heinrichs, Vonlanthen,
Fischbacher, & Fehr, 2008; Heinrichs, von Dawans, & Domes,
2009; Mikolajczak et al., 2010; Zak, Stanton, & Ahmadi, 2007).
Indeed, studies using healthy participants have shown that
intranasal inhalation of oxytocin can strengthen memory for
social but not non-social stimuli (Guastella, Mitchell, & Dadds,
2008), including faces (Rimmele et al., 2009; Savaskan et al.,
2008). However, the precise influence of oxytocin on face
memory remains unclear, as the hormone seems to only
improve the recognition of faces displaying particularconflicting findings. For instance, while Rimmele et al. (2009)
found oxytocin improved memory for faces displaying both
positive and negative expressions, Guastella et al. (2008)
observed improved memory for happy but not angry or
neutral faces, and Savaskan et al. (2008) reported improved
recognition of neutral and angry but not happy faces.
While the precise influence of oxytocin on face memory
remains to be unravelled, it is pertinent that the hormone has
also been found to influence processing strategy. Indeed,
oxytocin has been reported to increase the time spent looking
at the eye region of the face (Guastella et al., 2008), an area
thought to provide critical information for identification (Ellis,
Shepherd, & Davies, 1979; Young, McWeeny, Hay, & Ellis,
1986). It is of note that this shift in processing strategy has
also been reported in individuals with autistic spectrum dis-
order (Andari et al., 2010), who commonly experience face
recognition deficits (Schultz, 2005).
The findings discussed above suggest that intranasal
inhalation of oxytocin may also facilitate face recognition in
DP. The current investigation set out to address this issue,
investigating whether oxytocin can improve performance in
10 DPs and 10 matched control participants on a task that
assesses the encoding and recognition of new faces. In
addition, we also assessed performance on a face matching
task that assesses the ability to perceive facial identity
(thereby placing minimal demands on long-term memory for
faces). This issue is particularly relevant to the current study
given that some prosopagnosics also have face perception
deficits, and sequential models of face processing predict that
such impairments inevitably bring about recognition deficits
(e.g., Bruce & Young, 1986). This latter task also represents a
novel contribution to the literature, given that no studies
have examined the influence of oxytocin on face perception
skills.2. Methods
2.1. Design
The study used a randomized, placebo-controlled, double-
blind within-subject experimental design (AB-BA) to examine
the effects of a one-time 24 IU intranasal dose of oxytocin on
face processing performance in 10 individuals with DP and 10
matched control participants. Two face processing tests were
used to assess changes in performance: one that measured
memory for newly encoded faces, and one that measured the
perceptual ability to match faces of the same identity.
2.2. Participants
A group of 10 adults with DP took part in this study [seven
male, mean age ¼ 49.2 years, standard deviation (SD) ¼ 14.2].
All participants had contacted our laboratory because they
experience severe difficulties with face recognition in
everyday life. Prior to the investigation, each participant
attended an initial diagnostic testing session where they were
interviewed about their neuropsychological history and
Table 1 e Demographics of DPs and performance in SD units on tests of face processing, lower-level vision and object
recognition. DP scores are compared to published norms for each test.
Control
Mean (SD)
DP1 DP2 DP3 DP4 DP5 DP6 DP7 DP8 DP9 DP10
Age 63 63 64 65 51 47 34 30 44 31
Gender M M M F F M F M M M
Hand L R R R R L R R R R
IQ 119 119 119 125 119 113 122 119 119 117
Face processing tests
CFMT 59.6 (7.6) 3.76a 4.16a 2.71a 2.32a 3.50a 2.71a 2.97a 2.32a 3.37a 3.11a
CFPT 36.7 (12.2) 2.89a 1.25 1.25 1.75 .76 .76 1.91 2.89a 1.91 1.25
Famous faces 47.3 (6.2) 4.76a 3.92a 3.11a 2.15a 2.95a 4.24a 4.73a 3.60a 3.92a 3.92a
Mind in eyes 26.2 (3.6) 1.61 1.44 .22 1.61 1.06 1.17 1.33 1.33 1.44 .06
Lower-level vision
Length Match 26.9 (1.6) .69 .06 .69 1.19 1.19 .06 4.94a 1.81 1.31 3.06a
Size Match 27.3 (2.4) .29 .71 .29 .29 1.38 1.79 .13 1.38 .71 .96
Orientation Match 24.8 (2.6) 1.23 .46 1.23 .08 .46 1.23 .31 .85 1.62 .69
Position of gap 35.1 (4.0) .48 .53 .48 .23 1.23 .48 .98 .23 .73 .53
Object Decision test 114.7 (5.7) 1.11 .29 .93 .40 .75 .93 1.28 .93 1.28 2.05a
a Indicates impaired performance.
c o r t e x 5 0 ( 2 0 1 4 ) 5 5e6 3 57participated in a set of tests to confirm their prosopagnosia
(see Table 1). Indeed, previous work has indicated that both a
clinical interview (Grueter, Grueter, & Carbon, 2008) and
objective testing (Duchaine, 2008) are necessary for this pro-
cess. All participants shared personal anecdotes of instances
where they failed to recognize close friends and relatives, and
reported apparently lifelong and severe difficulties with face
recognition. No participant had experienced neurological
illness or trauma, and their difficulties were therefore regar-
ded as developmental in origin.
The neuropsychological testing battery has been used by
other researchers to diagnose DP (e.g., Bate et al., 2008;
Duchaine et al., 2007; Garrido et al., 2009), and appropriate
norms for each test were taken from accompanying research
publications or manuals. Face processing skills were assessed
using the Cambridge Face Memory Test (CFMT: Duchaine &
Nakayama, 2006), a famous faces test (Duchaine et al., 2007),
and the Cambridge Face Perception Test (CFPT: Duchaine
et al., 2007). While these are well-known tests that have
been described extensively elsewhere, it should be noted that
some DPs can achieve ‘normal’ scores on the CFMT by
adopting effective compensatory strategies. Nevertheless, we
only used participants who scored within the impaired range
on both this test and the famous faces test, given any
compensatory strategies may obscure the effects of oxytocin
on face recognition performance. It should also be noted that
poor performance on the CFPT is not necessary for a diagnosis
of prosopagnosia. Indeed, only some DPs demonstrate im-
pairments in face perception (in our sample only DP1 and DP8
were impaired on this test), and the condition is therefore
regarded as heterogeneous and may be composed of several
sub-types (Susilo & Duchaine, 2013). Similarly, while some
DPs have difficulties in recognizing facial expression, many
others do not struggle with this task (Bate et al., 2009).
Expression recognition skills were assessed in the DPs re-
ported here using the Reading the Mind in the Eyes test, and
when compared with appropriate published norming data
(Baron-Cohen, Wheelwright, Hill, Raste, & Plumb, 2001), no
deficits were observed.Lower-level vision was also assessed in order to check
whether the participants’ difficulties in face recognition were
underpinned by basic perceptual impairments. Four sub-tests
from the Birmingham Object Recognition Battery (BORB:
Humphreys & Riddoch, 1993) that have been used in previous
investigations (e.g., Bate, Cook, Mole, & Cole, 2013; Garrido
et al., 2009) were selected. In the Length Match test, partici-
pants are required to judge whether two lines are of the same
length; in the Size Match test they judge whether two circles
are of the same size; in the Orientation Match test they decide
whether two lines are parallel or not; and in the Position of the
Gap Match test they decide whether the position of the gap in
two circles is in the same place or not. Basic object recognition
was tested using the Object Decision test from the BORB. In
this test, the participant is presented with a series of line
drawings which depict animals or tools. In some trials the
drawings represent ‘unreal’ objects (i.e., the picture shows
half of one object combined with half of another object), and
the participant is asked to decide whether each of 128 draw-
ings represents a real or unreal object. Appropriate norming
data for these tests are presented within the BORB, and while
eight of the DP participants did not show any evidence of
lower-level perceptual difficulties, DP7 was impaired on the
Length Match test and DP10 was impaired on both the Length
Match and Object Decision tests. As described above, this may
reflect the heterogeneity of the condition and the possibility
that different sub-types of DP exist. Because DP7 and DP10
only performed poorly on one or two of the five sub-tests, any
lower-level visual impairments were not deemed to be severe
and the participants were not removed from our sample.
Ten control participants also participated in this study.
They were matched to the DP participants according to age
(M ¼ 46.8, SD ¼ 13.2), gender (seven male) and estimated IQ
[using the Wechsler Test of Adult Reading (WTAR): Wechsler,
2001]. All participants reported normal or corrected-to-normal
vision. Exclusion criteria were pregnancy, medication, signif-
icant medical or psychiatric illness, history of substance
abuse, and epilepsy. All participants provided written consent
and participated on a voluntary basis. The study was
Fig. 1 e Example trials from (A) the new versions of the CFMT and (B) the face matching tests.
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mouth University.
2.3. Measures
Face memory task: Two new versions of the CFMT (Duchaine &
Nakayama, 2006) were created for use in this experiment (see
Fig. 1A). The CFMT is a measure commonly used to assess
facial identity memory (Richler, Cheung, & Gauthier, 2011;
Wilmer, Germine, Chabris, et al., 2010) and to diagnose face
recognition impairments in adults (e.g., Avidan, Tanzer, &
Behrmann, 2011; Bate et al., 2008, 2009; Bowles et al., 2009;
Crookes & McKone, 2009; Furl, Garrido, Dolan, Driver, &
Duchaine, 2011; Rivolta, Schmalzl, Coltheart, & Palermo,
2010). The CFMT has demonstrated high reliability (Bowles
et al., 2009; Wilmer, Germine, Loken, et al., 2010) and both
convergent and divergent validity (Bowles et al., 2009; Dennett
et al., 2012; Wilmer, Germine, Chabris, et al., 2010; Wilmer,
Germine, Loken, et al., 2010). Alternate versions of the CFMT
have similar psychometric properties so the paradigm ap-
pears to be an effective means to assess face memory
(McKone et al., 2011; Wilmer, Germine, Loken, et al., 2010). In
the first part of the CFMT, participants are introduced to six
target faces and are then tested with forced-choice items
consisting of three faces, one of which is a target. For each
target face, three test items contain views identical to those
studied in the introduction, five present novel views, and four
present novel views with noise. At two points in the test,
participants are given the opportunity to review the target
faces before proceeding with the next set of trials (for full
details see Duchaine & Nakayama, 2006).
Given the effectiveness of the CFMT, we adopted its exact
design in preparing our face recognition tests for the current
study.However, itwas necessary to create twonewversions of
the test given (a) the within-subjects nature of our investiga-
tion, and (b) that all the DP participants had already completed
the original version in a previous testing session that
confirmed their prosopagnosia (see Table 1). The faces used in
the two new versions of the CFMT were generated using
FaceGen, a software package that generates life-like faces
while permitting the user absolute control over parameters
such as head angle, expression, distinguishing characteristics(e.g., freckles, blemishes), and external features thatmight cue
recognition (e.g., ear shape, hairline). An alternate version of
the CFMT also used FaceGen faces, and performance on it was
highly correlated with performance on the original CFMT
(Wilmer, Germine, Loken, et al., 2010).
The two new versions of the CFMTwere pilot tested prior to
onset of the experiment to ensure they were of equal diffi-
culty. Twenty unimpaired perceivers (10 male, mean
age ¼ 20.65 years, SD ¼ 2.85) completed both versions in the
same testing session (order of completion was counter-
balanced). A 2 (version)  2 (order) mixed design analysis of
variance (ANOVA) confirmed there was no difference in the
difficulty of the two versions of the test [version 1: M ¼ 57.50,
standard error (SE) ¼ 1.94; version 2: M ¼ 57.05, SE ¼ 2.25],
F(1,18) ¼ .115, p ¼ .739, ƞp2 ¼ .006. Further, there was no dif-
ference in performance for the test completed first compared
to that completed second, irrespective of version,
F(1,18)¼ .019, p¼ .892, ƞp2 ¼ .001. Finally, the order in which the
two versions were completed did not interact with test
version, F(1,18) ¼ 1.936, p ¼ .181, ƞp2 ¼ .097.
Face perception task: To assess the influence of oxytocin on
face perception, two versions of a face matching test were
created (see Fig. 1B). This test was designed to measure
participants’ ability to match faces of the same identity,
without placing any demands on long-term face memory.
Each version of the test contained 40 trials in which a target
face was positioned at the top of the screen, and a triad of
test images was placed below. Participants were instructed to
select the test image that matched the identity of the person
displayed in the target image. Forty male and 40 female facial
identities were selected from the Bosphorus Face Database
(Savran, Sankur, & Bilge, 2012), and different facial identities
were used in the two versions of the test (20 male and 20
female in each). All faces displayed neutral expressions and
were cropped to exclude any external features that might aid
performance. In each trial, the target image was displayed
from a frontal perspective, and was reduced in size and
darkened in colour from the test images, to prevent partici-
pants using low-level visual properties of the images to aid
performance. Head direction of the test images was varied
across the trials. Specifically, in each version, eight trials
displayed faces from each of a frontal, 1/3 left profile, 1/3
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perspective. The same participants as described above
completed a pilot test to ensure the two versions were of
equal difficulty, and no difference in scores was noted
(version 1:M ¼ 31.20, SE ¼ 1.03; version 2:M ¼ 30.95, SE ¼ .77),
F(1,18) ¼ .080, p ¼ .781, ƞp2 ¼ .004. Again, scores were not
influenced by order of completion, F(1,18) ¼ .119, p ¼ .734,
ƞp2 ¼ .007 and F(1,18) ¼ .157, p ¼ .697, ƞp2 ¼ .009.
2.4. Procedure
Participants were asked to abstain from food and drink other
than water for 2 h before the experiment; and from alcohol,
smoking and caffeine for 24 h before the experiment. Each
participant visited the laboratory on two occasions, separated
by a 14e25 (M ¼ 16.55, SD ¼ 5.07) day interval, dependent on
participant availability. The length of the interval between
testing sessions did not vary for DP compared to control par-
ticipants, F(1,18) ¼ .690, p ¼ .417 ƞp2 ¼ .037. On each visit, par-
ticipants received a single intranasal dose of 24 IU oxytocin
(Syntocinon Spray, Novartis; three puffs per nostril, each with
4 IU oxytocin) or placebo spray. The placebo spray was pre-
pared by an independent pharmaceutical company, and
contained exactly the same ingredients as the experimental
spray with the exception of the oxytocin. Preparation of the
sprays by an independent company also ensured the experi-
ment was double-blind, and the two sprays were identified by
colour rather than their actual identity (i.e., oxytocin or pla-
cebo), which was only revealed after data analysis was com-
plete. The order in which participants received the two sprays
was randomized, and the 24 IU dose was selected according to
previous experimental work that utilised this dosage (e.g.,
Guastella et al., 2008; Rimmele et al., 2009).
Following inhalation, participants sat quietly for 45 min,
the length of time it is believed to take for central oxytocin
levels to plateau (Born et al., 2002). Participants were
instructed to bring a book or magazine to read during this
time. Following the rest period, participants completed the
two face processing tasks in the same order (commencing
with the face memory task), in order to ensure equality of
central oxytocin levels for each test. General affect was
measured throughout the experiment using the Multidimen-
sional Mood Questionnaire (MMQ: Steyer, Schwenkmezger,
Notz, & Eid, 1997), to assess the possible mood-altering ef-
fects of oxytocin, and to control for non-specific effects of
attention and wakefulness (the MMQ is composed of three
sub-scales: goodebad, awakeetired and calmenervous). Each
participant was required to complete the MMQ at three in-
tervals across the experiment: immediately following inha-
lation, after the 45 min resting period, and after the two face
processing tests had been completed. Finally, the experi-
menter enquired about adverse side effects during the testing
session and again 24 h after test completion.
2.5. Statistical analyses
Statistical analyses were conducted on the MMQ results
collected across the testing sessions and on the behavioural
data collected from the two face processing tasks. Scores on
the MMQ were calculated according to the three sub-scales,and data were entered into a 2 (spray: oxytocin, placebo)  3
(time of MMQ completion: after inhalation, after rest, end of
session)  2 (group: DP, control) mixed factorial MANOVA.
Scores for the two face processing tests were entered into a 2
(spray: oxytocin, placebo)  2 (group: DP, control) mixed
factorial multivariate analysis of variance (MANOVA). The
data file for one DP participant was unreadable in the placebo
condition of the CFMT, and was therefore not included in the
analysis of this test. Additional comparisons were carried out
to investigate (a) whether DP performance in the oxytocin
condition fell within the same range as control placebo per-
formance, and (b) whether the severity of each individual’s
prosopagnosia correlated with the extent of their improve-
ment on the two tasks. For the latter analyses, scores obtained
on the original version of the CFMT and the CFPT (i.e., the tests
run within the original diagnostic session: see Table 1) were
correlated against the level of improvement in the oxytocin
condition (oxytocin performanceminus placebo performance)
of the CFMT and matching test, respectively.3. Results
3.1. Adverse side effects and MMQ
Adverse side effects were only reported by one DP participant
following inhalation of either spray. Specifically, this indi-
vidual reported a slight headache immediately after oxytocin
inhalation, but this had disappeared by the 24-h follow-up. A
mixed factorial MANOVA revealed no main effect of spray or
group, F(3,16) ¼ .569, p ¼ .643, ƞp2 ¼ .096 and F(3,16) ¼ 1.597,
p ¼ .229, ƞp2 ¼ .230, although the interaction between the two
factors approached significance, F(3,16) ¼ 2.904, p ¼ .067,
ƞp2 ¼ .353. This latter effect was driven by the control (but not
DP) participants feeling ‘better’ according to the goodebad
scale in the oxytocin condition, while the DP but not the
control participants felt calmer in the oxytocin condition.
There was a main effect of time, F(6,13) ¼ 4.271, p ¼ .014,
ƞp2 ¼ .663, and further analyses revealed this was driven by an
increase in wakefulness after the 45 min resting period,
F(2,36) ¼ 4.626, p ¼ .016, ƞp2 ¼ .204. However, this effect did not
interact with participant group or spray, F(2,36) ¼ 1.914,
p ¼ .162, ƞp2 ¼ .096 and F(2,36) ¼ .225, p ¼ .800, ƞp2 ¼ .012.
3.2. Face processing tests
A mixed factorial MANOVA revealed a significant improve-
ment in the oxytocin compared to the placebo condition,
F(2,16) ¼ 5.944, p ¼ .012, ƞp2 ¼ .426. Univariate tests confirmed
that performance was better in the oxytocin rather than the
placebo condition on both the CFMT (oxytocin: M ¼ 56.89,
SE ¼ 1.79; placebo: M ¼ 53.93, SE ¼ 2.14) and matching test
(oxytocin: M ¼ 33.11, SE ¼ .76; placebo: M ¼ 31.10, SE ¼ .96),
F(1,17) ¼ 4.975, p ¼ .039, ƞp2 ¼ .226 and F(1,17) ¼ 5.786, p ¼ .028,
ƞp2 ¼ .254. While there was no main effect of group on the
multivariate analysis, F(2,16) ¼ 2.307, p ¼ .132, ƞp2 ¼ .224, group
and spray did interact, F(2,16) ¼ 4.422, p ¼ .030, ƞp2 ¼ .356.
Univariate analyses confirmed that this interaction was
driven by a greater improvement on the CFMT in DPs
compared to controls, but the same effect was not significant
Fig. 2 e Performance of DP and control participants under
placebo and oxytocin conditions in (A) the CFMT
(maximum score of 72) and (B) the face matching test
(maximum score of 40). Asterisks indicate significant
between- and within-group differences.
Fig. 3 e (A) Scores on the original version of the CFMT
plotted against the level of improvement in the oxytocin
condition on the new versions of the CFMT (i.e., the
difference between the scores achieved in the oxytocin and
placebo conditions), and (B) scores on the CFPT plotted
against the level of improvement in the oxytocin condition
on the face matching tests.
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F(1,17) ¼ 2.098, p ¼ .166, ƞp2 ¼ .110 (see Fig. 2). Follow-up com-
parisons found that while the performance of DPs improved in
the oxytocin condition for both the CFMT and matching test,
F(1,8) ¼ 7.667, p ¼ .024, ƞp2 ¼ .489 and F(1,9) ¼ 9.238, p ¼ .014,
ƞp2 ¼ .507, the same pattern was not observed in control par-
ticipants, F(1,9) ¼ .040, p ¼ .847, ƞp2 ¼ .004 and F(1,9) ¼ .482,
p ¼ .505, ƞp2 ¼ .051.
Further analyses focused on the performance of the DP
group. While, DP performance in the CFMT placebo condition
was significantly lower than that of controls, F(1,17) ¼ 6.308,
p ¼ .025, ƞp2 ¼ .262, their performance in this condition was
greater than their performance on the original diagnostic
version of the CFMT (i.e., the version completed within the
diagnostic session: see Table 1), F(1,8) ¼ 8.228, p ¼ .021,
ƞp2 ¼ .507. It is possible that this differencemay be attributed to
a placebo effect, but potential practice effects and the funda-
mental differences between the stimuli in the experimental
CFMTs compared to the original version make this observa-
tion tentative. Strikingly, DP performance in the oxytocin
condition did not differ from that of controls, F(1,18) ¼ 1.257,
p ¼ .277, ƞp2 ¼ .065, and a similar pattern was observed in the
matching test. Indeed, while DP performance in the placebocondition remained lower than control placebo performance,
F(1,18) ¼ 6.322, p ¼ .022, ƞp2 ¼ .260, DP performance in the
oxytocin condition did not differ from control oxytocin scores,
F(1,18) ¼ 2.266, p ¼ .150, ƞp2 ¼ .112.
A final set of analyses investigated whether the severity of
each individual’s prosopagnosia predicted the extent of their
improvement in the oxytocin condition. Performance on the
original version of the CFMT (from the diagnostic session) did
not correlate with the extent of the improvement in the
experimental CFMT, r ¼ .352, n ¼ 9, p ¼ .353. Likewise, perfor-
mance on the CFPT (a face perception test from the diagnostic
session) did not correlate with the extent of improvement on
the matching test, r ¼ .073, n ¼ 10, p ¼ .842 (see Fig. 3).4. Discussion
This investigation aimed to examine whether intranasal
inhalation of the hormone oxytocin improves face processing
in a group of individuals with DP. Participants were asked to
complete two face processing tests after inhaling either
oxytocin or placebo nasal spray: a face memory task that
required participants to encode and recall a set of six faces,
and a face matching task that required participants to match
simultaneously presented faces according to their identity. An
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tion, but only for DP and not control participants. Analysis of
responses on the MMQ indicates that these findings cannot be
attributed to non-specific changes in attention, mood or
wakefulness.
Importantly, there are two novel findings from the DP
group. First, we have presented the first evidence that
oxytocin can temporarily improve face recognition in the
condition, as has been observed in some investigations using
typical perceivers (e.g., Rimmele et al., 2009; Savaskan et al.,
2008; but see below for a discussion of this issue). Findings
from recent neuroimaging investigations permit speculation
of the potential neural underpinnings of this effect. Indeed,
Haxby et al. (2000) identified three structures that are thought
to compose a ‘core’ face neural processing system: an occipital
face area (OFA) that has been implicated in the early visual
processing of faces (e.g., Pitcher, Walsh, & Duchaine, 2011),
the fusiform face area (FFA) that is believed to process facial
identity (e.g., Kanwisher, McDermott, & Chun, 1997), and the
superior temporal sulcus (STS) which is thought to process
changeable social aspects of the face, such as expression and
eye gaze direction (e.g., Hoffman & Haxby, 2000). Although no
work to date has recorded brain activity while participants
attempt to recognize facial identity under oxytocin condi-
tions, there is some indication from emotional expression
recognition tasks that the hormone modulates activity in the
distributed face processing network. Notably, a modulation in
activity in the FFA has been reported while participants
recognize emotional expressions under oxytocin conditions
(Domes et al., 2007, 2010; Kirsch et al., 2005; Labuschagne et al.,
2010; Petrovic, Kalisch, Singer, & Dolan, 2008), and it is likely
that increased activity in this region might underpin the
heightened recognition performance in the oxytocin condi-
tion reported here. In addition, several investigations have
provided evidence that the amygdalamight have a critical role
in the mediation of the socio-cognitive effects of oxytocin
(Domes et al., 2007; Kirsch et al., 2005; Petrovic et al., 2008), and
it is of note that this neural structure is thought to be part of
the extended face processing system that acts in concert with
the core system (Haxby et al., 2000).
A second novel finding reported here is that, in the DP
participants, oxytocin improved the perception of facial
identity in a face matching task. To our knowledge this is the
first evidence that oxytocin can improve face perception in
any participant group, providing further insight into the locus
of the effects of the hormone. However, neuroimaging work
examining the influence of oxytocin on face perception is
required. Indeed, while it is plausible that enhanced fusiform
activity promotes performance on both face memory and face
perception tasks, it is currently unknown whether oxytocin
can also promote activity in neural structures implicated in
earlier stages of the face processing network, such as the OFA
(although modulation in occipital areas was noted by Domes
et al., 2010). Nevertheless, we can speculate that our findings
imply that oxytocin acts upon neural structures that are open
to modulation even in DP, despite possible abnormalities in
these areas (see Garrido et al., 2009; Hasson, Avidan, Deouell,
Bentin, & Malach, 2003; Thomas et al., 2009).
When considering the influence of oxytocin on facial
perception, it is pertinent to examine each individual DP’sneuropsychological background in relation to their improve-
ment in the oxytocin condition. Indeed, while all DPs have a
deficit in face recognition, an impairment in the perception of
facial identity (i.e., when no demands are placed on memory)
is not necessary for a diagnosis of the condition. This is one
example of the heterogeneity of DP, and it is of note that only
two participants (DP1 and DP8) in our sample were impaired
on the CFPT in the initial diagnostic session. Although no
overall correlation was noted between initial CFPT perfor-
mance and level of improvement on the face matching test, it
is relevant that oxytocin brought about one of the largest
improvements on this test in DP1, although DP8 did not show
any improvement. In addition, DP7 and DP10 presented with
some difficulties in lower-level vision on tests of the BORB in
the diagnostic session, although their CFPT scores were in the
normal range. Unfortunately DP7’s data were lost for the
CFMT in the placebo condition, but he displayed a small
improvment in the matching test in the oxytocin condition.
DP10 displayed very little improvement on both tests in the
oxytocin condition. Thus, while examination of the partici-
pants on an individual basis suggests that those with lower-
level visual impairments may be less susceptible to the
effects of oxytocin, it is more difficult to make inferences
based on the presence or absence of face perception deficits.
In part, this can be attributed to the small sample size, and
future work needs to further examine these issues in a much
larger participant group.
It may also be the case that a ‘placebo effect’ is at work in
some DP participants, and this may obscure other findings in
the study. Indeed, standard errors were larger in the placebo
compared to the oxytocin condition in the DPs, indicating that
some participants were more influenced by the placebo spray
than others. This suggestion is supported by the finding that
the DPs achieved higher scores on the experimental CFMT in
the placebo condition than in the original version adminis-
tered in the initial diagnostic session. However, some caution
must be exercised when interpreting this observation, as it is
unclear whether the finding actually reflects a placebo effect.
Indeed, it is likely that the higher scores in the placebo con-
dition were brought about by practice effects (the DPs had
completed at least one version of the CFMT before partici-
pating in the placebo condition and were therefore aware of
the nature of the task), and the computer-generated stimuli
used in the experimental CFMT may be more vulnerable to
compensatory strategies (e.g., the use of feature-matching)
than the ‘real’ faces used in the original version. Unfortu-
nately, the available data from the control participants do not
provide further insight into this issue, as these participants
did not complete the original version of the CFMT (no initial
diagnostic session was required for these individuals). Hence,
while it is possible that a placebo effect was at work at least in
the DP participants, the design of the current study and
available data do not permit firm conclusions to be drawn on
this issue.
The lack of significance in the correlations between DP
severity and extent of improvement under oxytocin condi-
tions provides some insight into the finding that control per-
formance was not influenced by oxytocin in either task.
Indeed, it may be the case that oxytocin has a greater effect in
individuals with poorer face processing skills, and at a group-
c o r t e x 5 0 ( 2 0 1 4 ) 5 5e6 362level, the data presentedhere support this claim.However, it is
evident from the discussion above that this is a complex issue,
and examination of the DPs on a case-by-case basis suggests
the influence of other factors. It is also of note that the pattern
of findings observed in the controls speaks to previous work
that reports conflicting findings for typical viewers recog-
nizing faces that display different emotional expressions.
Indeed, only faces displaying neutral expressionswere used in
the tasks reported here, and the lack of improvement in con-
trol participants fitswellwith the finding reported byGuastella
et al. (2008), where oxytocin only improved the recognition of
happy and not angry or neutral faces. On the other hand,
Savaskan et al. (2008) reported the reverse finding, where
oxytocin improved the recognition of neutral and angry but
not happy faces, and it is therefore clear that we do not have a
firm understanding of the interaction between oxytocin, face
memory and emotional expression. If it is the case that
emotional expression interferes with the capacity of oxytocin
to improve face recognition, our findings raise the possibility
that expression interferes to a greater extent for unimpaired
perceivers than DPs. Alternatively, it may simply be the case
that the impaired face processing system ismore amenable to
improvement than the normal face processing system. How-
ever, these comments are merely speculative, and again
further work is required to investigate this issue.
Finally, our findings have implications for the development
of intervention strategies in disorders that present with face
recognition impairments. While several studies have exam-
ined the potential therapeutic role of oxytocin in relieving
symptoms in autistic spectrum disorders, obsessive compul-
sive disorder, post-traumatic stress disorder, personality dis-
orders, anxiety disorders, schizophrenia and depression (for
reviews see Ishak, Kahloon, & Fakhry, 2011; Macdonald &
Macdonald, 2010), this study is the first to report its effec-
tiveness in DP. This is an important issue given that face
processing impairments do not only present in DP, but also
following brain injury, degenerative disease, and in socio-
developmental disorders such as autism, William’s syn-
drome and Turner’s syndrome. Thus, future work might
examine whether oxytocin can improve face processing im-
pairments in all conditions regardless of aetiology, or whether
it is only effective in certain disorders. Further, while the
current study examined the influence of a single dose of
oxytocin in bringing about a temporary improvement in face
processing in DP, further work might also consider the ther-
apeutic value of repetitive inhalation of oxytocin in this con-
dition and the sustainability of any improvements.r e f e r e n c e s
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